NCT01585701View on ClinicalTrials.gov

Phase I Study of AT13148, a Novel AGC Kinase Inhibitor

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

January 10, 2018

Study Completion Date

January 10, 2018

Conditions
Advanced Solid Tumours
Interventions
BIOLOGICAL

AT13148

Days 1, 3, 5 of a weekly schedule in dose escalation cohorts of three patients. Continuous dosing until progression or unacceptable toxicity develops up to a maximum of 12 cycles.

Trial Locations (1)

SM2 5PT

Royal Marsden Hospital, Institute of Cancer Research, Sutton

Sponsors

Lead Sponsor

Cancer Research UK
All Listed Sponsors
lead

Cancer Research UK

OTHER

NCT01585701 - Phase I Study of AT13148, a Novel AGC Kinase Inhibitor | Biotech Hunter | Biotech Hunter